FDA Brief

Warning letters Drugs

FDA warning letter to

Bertrand P. Cole, D.O.

High riskIssued Feb 2Posted Feb 17Center for Drug Evaluation and Research (CDER)

FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

What happened

FDA inspected Dr. Cole's clinical site from May 12 to 16, 2025, as part of its program to check research conduct. FDA found that all four enrolled subjects received 10 mg of the study drug at multiple visits, even though their assigned maximum weekly doses were 1.5, 4.5, or 9.0 mg. The subjects had nausea, vomiting, stomach pain, fatigue, dizziness, heartburn, and injection-site reactions while receiving the wrong doses.

What FDA found

  1. Dr. Cole did not ensure the study was run according to the investigational plan (the study's required procedures).

    21 CFR 312.60
  2. All four enrolled subjects received 10 mg of study drug at multiple visits, above their assigned maximum weekly target doses.

    21 CFR 312.60
  3. Subjects had multiple adverse events while receiving the incorrect doses.

    21 CFR 312.60
  4. Site staff who gave the study drug were not originally delegated and trained for that task, according to the company's response.

  5. The company's response lacked enough detail on training, procedures, and investigator oversight to prevent repeat violations.

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. Include details on training, procedures, and how the investigator will oversee study procedures.

Who should pay attention

  • clinical trial sponsors
  • contract research organizations
  • clinical investigators and site staff

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  3. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk